Please find the next edition of the Monthly Infectious Diseases Summary, our subjective look at the most important news of the month. Please let us know how you like it and if there is something interesting we missed by contacting us at nac.contact@lgcgroup.com

Europe’s Deadliest Tick-Borne Virus Returns: Four CCHF Cases Reported in Spain

Crimean-Congo haemorrhagic fever (CCHF), a severe tick-borne disease with reported fatality rates of up to 40%, remains under close surveillance across Europe. In 2026, Spain has reported four locally acquired cases.

With tick season still ongoing across many parts of Europe, health authorities are urging people spending time outdoors to take precautions against tick bites. The virus is transmitted primarily by Hyalomma ticks, which are established across southern Europe and are increasingly attracting public health attention. Communicable disease threats report, 19-25 September, week 39

To support surveillance, diagnostic development and vaccine research, The Native Antigen Company offers a portfolio of CCHF antigens, including recombinant nucleoproteins and glycoproteins, alongside hundreds of viral, bacterial and parasitic antigens that enable infectious disease research worldwide. Crimean Congo Hemorrhagic Fever Virus - The Native Antigen Company

Bundibugyo Ebola Outbreak Continues to Escalate in DRC

The ongoing Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo has reached a worrying new milestone, with 7,890 confirmed cases and 3,799 deaths reported as of 23 September 2026, representing a case fatality rate of 48.1%. Since the beginning of September alone, more than 1,100 new cases and 500 deaths have been recorded, while the outbreak has now spread to 63 health zones across seven provinces, increasing concerns around further regional transmission. Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo

With no approved vaccine or specific treatment currently available for Bundibugyo Ebola, rapid diagnosis and surveillance remain critical. To support researchers and diagnostic developers responding to this unprecedented outbreak, The Native Antigen Company has recently launched a recombinant Bundibugyo Ebola GP1 antigen, with a recombinant nucleoprotein (NP) antigen coming soon. These additions complement TNAC's extensive portfolio of Ebola and filovirus reagents, supporting assay development, epidemiological studies, and outbreak preparedness. Bundibugyo Ebola Virus (BDBV) glycoprotein 1 (GP1)

First Breeding Population of Dengue Mosquito Found in London 

In a development that has caught the attention of public health experts, Aedes aegypti, the mosquito responsible for spreading dengue, Zika, chikungunya and yellow fever, has been found breeding in east London for the first time. While UKHSA stresses that the current risk to the public remains low and no human infections have been linked to the discovery, the finding highlights how climate change and global travel are increasing opportunities for invasive disease vectors to appear in new regions. Invasive mosquitoes breed in London for the first time in the UK - BBC News

As mosquito-borne diseases continue to expand their geographic reach, The Native Antigen Company supports surveillance, diagnostic development and vaccine research with an extensive portfolio of arboviral antigens, including dengue (all four serotypes), Zika, chikungunya, yellow fever, West Nile virus and Japanese encephalitis virus reagents. Have a look at our matched antibody pairs available here: Matched Pair Antibodies - The Native Antigen Company

Learning In The Field: 7 Weeks In South Sudan

SSPE, the Long Shadow of Measles

Viral Hemorrhagic Fever Preparedness

Non-neutralizing antibody responses control acute Crimean-Congo hemorrhagic fever virus infection in naïve mice | Journal of Virology using multiple of our CCHF proteins

Virus-like particle display of consensus α-neurotoxins does not enhance neutralising antibody responses against elapid venoms - ScienceDirect featuring our custom snake venom! Reach out if you require any custom protein services, like this one.

Just a reminder that all the researchers publishing with us are eligible for discount on their next order, so please do not hesitate to reach out and show off your publication!

Exciting additions are coming to the The Native Antigen Company portfolio, including recombinant Anti-TSHR for thyroid autoimmunity, Anti-Borrelia burgdorferi OspC for Lyme disease serology, and CA125 to expand our growing Cancer Biomarker portfolio.

New reagents. More diagnostic assay development possibilities. Reliable recombinant solutions from The Native Antigen Company.

Trade Shows: 

• World Vaccine Congress
  • Amsterdam, Netherlands
  • October 20-21, 2026
  • Booth #316 - Schedule time with our team
  • Speaking Engagement: Virus-like particles as tools to support vaccine development - Holger Hannemann | Director of R&D, Antigens and Reagent

Webinar: 

• VLPs as serological tools for diagnostics and vaccine development
  • Join this webinar to see how VLPs move from production and scale-up to serological applications, and what this could mean for your own diagnostic or vaccine development work.
  • November 18, 2026 8AM ET

Visit our References page to view all the peer-reviewed publications we've collated.